Rucaparib
Indication: BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer
Population PK simulator for rucaparib, an oral PARP inhibitor used in BRCA-associated ovarian cancer. Two-compartment model with sequential absorption based on FDA clinical pharmacology analyses.
Drug Overview
Clinical Context
- Molecular Target
- PARP1, PARP2, and PARP3
- Drug Class
- PARP Inhibitor
- Therapeutic Area
- Oncology / Ovarian Cancer
- Indication
- BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer
- Route of Administration
- Oral
Model Information
- Model Type
- Population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Rucaparib allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this parp inhibitor following oral administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Rucaparib PK simulator?
This is a free, interactive pharmacokinetic simulator for Rucaparib used in BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Rucaparib belong to?
Rucaparib is classified as a PARP Inhibitor that targets PARP1, PARP2, and PARP3. It is used in the Oncology / Ovarian Cancer therapeutic area.
What route of administration does this model simulate?
This simulator models Oral administration of Rucaparib. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
rucaparib pk-pd model
PARP-targeted therapy in advanced solid tumors including ovarian cancer
rucaparib ok model
Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC)
Ready to Simulate?
Launch the Rucaparib simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community